US3965254A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions for the treatment of calcific tumors
Assignee: Procter and Gamble Co
•
Filing: 1974-11-15
•
Granted: 1976-06-22
•
Expires: 1994-11-15
Abstract
Abstract Composition in unit dosage form comprising mono-, di- and polyphosphonate compounds having therapeutic levels of radioactive phosphorus (as 32 P and 33 P) incorporated therein are disclosed. Due to the extremely high affinity of the polyphosphonate compounds for active bone tumors and their exceptionally low retention in soft tissue they are ideal for therapy of both primary and metastatic bone tumors and soft tissue tumors which calcify.
Inventors
- 👤 Andrew John Tofe
- 👤 Marion David Francis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 22:27
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0489; A61K2121/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
210 words
A sterile dilute composition in unit dosage form comprising from about 2 to 20 millicuries of a 32 P or 33 P tagged polyphosphonate compound suitable for the treatment of calcific tumors selected from the group consisting of: ##EQU9## wherein each R is hydrogen or CH 2 OH and n is an integer of from 3 to 10; ##EQU10## wherein R 1 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, hydroxyl, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or -CH 2 C(PO 3 H 2 ) 2n -H where n is 1 to 15, R 2 is hydrogen, lower alkyl, amino benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 Ch 2 PO 3 H 2; ##EQU11## wherein n is an integer of from 3 to 9; ##EQU12## wherein each R 3 is hydrogen or lower alkyl (e.g., methyl, ethyl, propyl and butyl); ##EQU13## wherein n is an integer of from 2 to 4; ##EQU14## wherein X and Y are each hydrogen or hydroxy; and the pharmaceutically acceptable salts of each of the foregoing acids.
Claim 2
Dependent Claim
210 words
A sterile dilute composition in unit dosage form comprising from about 2 to 20 millicuries of a 32 P or 33 P tagged polyphosphonate compound suitable for the treatment of calcific tumors selected from the group consisting of: ##EQU9## wherein each R is hydrogen or CH 2 OH and n is an integer of from 3 to 10; ##EQU10## wherein R 1 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, hydroxyl, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or -CH 2 C(PO 3 H 2 ) 2n -H where n is 1 to 15, R 2 is hydrogen, lower alkyl, amino benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 Ch 2 PO 3 H 2; ##EQU11## wherein n is an integer of from 3 to 9; ##EQU12## wherein each R 3 is hydrogen or lower alkyl (e.g., methyl, ethyl, propyl and butyl); ##EQU13## wherein n is an integer of from 2 to 4; ##EQU14## wherein X and Y are each hydrogen or hydroxy; and the pharmaceutically acceptable salts of each of the foregoing acids.
Claim 3
Dependent Claim
17 words
The composition of Claim 1 wherein the polyphosphonate is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
16 words
The composition of Claim 1 wherein the polyphosphonate is dichloromethanediphosphonic acid or a pharmaceutically acceptable salt.
Claim 5
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is tris (phosphonomethyl)amine or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is methanecyclohexylhydroxydiphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
16 words
The composition of claim 1 wherein the polyphosphonate is 3,3,4,4,5,5-hexafluoro-1,2-diphosphonocyclopent-1-ene or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
18 words
The composition of claim 1 wherein the polyphosphonate is cyclic tetraphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is ethene-1,2-dicarboxy-1-phosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
17 words
The composition of claim 1 wherein the polyphosphonate is ethane-1,2-dicarboxy-1,2-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 11
Independent Claim
209 words
A method for the treatment of calcific tumors comprising systemically administering to an animal afflicted therewith a safe but effective dose of a radioactive compound tagged with 32 P or 33 P selected from the group consisting of: ##EQU15## wherein each R is hydrogen or CH 2 OH or CH 2 OH and n is an integer of from 3 to 10, ##EQU16## wherein R 1 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, hydroxyl, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , -CH(PO 3 H 2 ) (OH), or --[CH 2 C(PO 3 H 2 ] n -H, where n is 1 to 15, R 2 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 Ch 2 PO 3 H 2; ##EQU17## wherein n is an integer of from 3 to 9, ##EQU18## wherein each R 3 is hydrogen or lower alkyl (e.g., methyl, ethyl, propyl and butyl); ##EQU19## wherein n is an integer of from 2 to 4; ##EQU20## wherein X and Y are each hydrogen or hydroxy; and the pharmaceutically acceptable salts thereof.
Claim 12
Independent Claim
209 words
A method for the treatment of calcific tumors comprising systemically administering to an animal afflicted therewith a safe but effective dose of a radioactive compound tagged with 32 P or 33 P selected from the group consisting of: ##EQU15## wherein each R is hydrogen or CH 2 OH or CH 2 OH and n is an integer of from 3 to 10, ##EQU16## wherein R 1 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, hydroxyl, amino, substituted amino, --CH 2 COOH, --CH 2 PO 3 H 2 , -CH(PO 3 H 2 ) (OH), or --[CH 2 C(PO 3 H 2 ] n -H, where n is 1 to 15, R 2 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or --CH 2 Ch 2 PO 3 H 2; ##EQU17## wherein n is an integer of from 3 to 9, ##EQU18## wherein each R 3 is hydrogen or lower alkyl (e.g., methyl, ethyl, propyl and butyl); ##EQU19## wherein n is an integer of from 2 to 4; ##EQU20## wherein X and Y are each hydrogen or hydroxy; and the pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim
17 words
The method of claim 10 wherein said compound is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
17 words
The method of claim 10 wherein said compound is dichloromethanediphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 15
Independent Claim
232 words
A method for the treatment of calcific tumors comprising systemically administering to an animal affected therewith a safe but effective dose of a radioactive compound tagged with 32 P or 33 P selected from the group consisting of: ##EQU21## wherein each R is hydrogen or CH 2 OH and n is an integer of from 3 to 10; ##EQU22## wherein R 1 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, hydroxyl, amino, substituted amino, --CH 2 COOH, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or -[CH 2 C(PO 3 H 2 ) 2 ] n -H, where n is 1 to 15, R 2 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or CH 2 CH 2 PO 3 H 2; ##EQU23## wherein n is an integer of from 3 to 9; ##EQU24## wherein each R 3 is hydrogen or lower alkyl (e.g., methyl, ethyl, propyl and butyl); ##EQU25## wherein nis an integer of from 2 to 4; ##EQU26## wherein X and Y are each hydrogen or hydroxy; and the pharmaceutically acceptable salts thereof; and subsequently administering a chemotherapeutic agent selected from the group consisting of: alkylating agents; antimetabolites; antibiotics; vinca alkaloids; hormones; enzymes; hydroxyurea; and procabazine.
Claim 16
Independent Claim
232 words
A method for the treatment of calcific tumors comprising systemically administering to an animal affected therewith a safe but effective dose of a radioactive compound tagged with 32 P or 33 P selected from the group consisting of: ##EQU21## wherein each R is hydrogen or CH 2 OH and n is an integer of from 3 to 10; ##EQU22## wherein R 1 is hydrogen, alkyl containing from 1 to about 20 carbon atoms, alkenyl containing from 2 to about 20 carbon atoms, aryl, phenylethenyl, benzyl, halogen, hydroxyl, amino, substituted amino, --CH 2 COOH, --CH 2 COOH, --CH 2 PO 3 H 2 , --CH(PO 3 H 2 ) (OH), or -[CH 2 C(PO 3 H 2 ) 2 ] n -H, where n is 1 to 15, R 2 is hydrogen, lower alkyl, amino, benzyl, halogen, hydroxyl, --CH 2 COOH, --CH 2 PO 3 H 2 , or CH 2 CH 2 PO 3 H 2; ##EQU23## wherein n is an integer of from 3 to 9; ##EQU24## wherein each R 3 is hydrogen or lower alkyl (e.g., methyl, ethyl, propyl and butyl); ##EQU25## wherein nis an integer of from 2 to 4; ##EQU26## wherein X and Y are each hydrogen or hydroxy; and the pharmaceutically acceptable salts thereof; and subsequently administering a chemotherapeutic agent selected from the group consisting of: alkylating agents; antimetabolites; antibiotics; vinca alkaloids; hormones; enzymes; hydroxyurea; and procabazine.
Claim 17
Dependent Claim
17 words
The method of claim 13 wherein said compound is ethane-1-hydroxy-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.
Claim 18
Dependent Claim
17 words
The method of claim 13 wherein said compound is dichloromethanediphosphonic acid or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US3213129A
Cited
US3336221A
Cited
US3387024A
Cited
US3400151A
Cited
US3532639A
Cited
US3553314A
Cited
US3553315A
Cited
US3579570A
Cited
US3743688A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-22 | 1979-12-22 | 1980-06-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-22 | 1983-12-22 | 1984-06-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-22 | 1987-12-22 | 1988-06-22 | $7700.00 | Window Closed / Lapsed |